通过查阅近几年国内外有关三氧化砷（As2O3）研究资料,对As2O3治疗肝癌的体内体外实验研究、临床试验及新剂型研究进行了综述。临床试验表明静脉注射给药治疗原发性肝癌,在规定的药物剂量范围内毒副作用较小,且疗效确切,可以用于肝癌预防和治疗,显示出可喜的前景;As2O3抗肝癌机制研究已逐步深入,还开展了联合用药研究等;但是新剂型研究很少。因而应加强高效、低毒、定向的新型给药系统的研究,使As2O3成为更理想的治疗肝癌药物。

This article summarizes the in vivo and in vitro experimental studies on the treatment of the cancer of the liver by As2O3 and on the clinical experiment and form of this drug by the way of consulting literatures about the study of As2O3 in China and abroad recent years. Clinical experiments show that in the treatment of primary cancer of the liver by intravenous injection of As2O3 and within the fixed doses the toxisity and side effects of this drug are relatively small and definite effectiveness can be acquired. Therefore it is able to be used for the prevention and treatment of the cancer of the liver, demonstrating encouraging prospects. The study on the mechanisms of As2O3 against the cancer of the liver has gone deeply and combined administration in the treatment is being studied; nevertheless, the study of new forms of the drag is very short. In view of this, studies on systems of new administration with high effectiveness but low toxisity and set direction should be strengthened in order that As2O3 may become an ideal drug in the treatment of the cancer of the liver.